全文获取类型
收费全文 | 1328篇 |
免费 | 48篇 |
国内免费 | 81篇 |
专业分类
耳鼻咽喉 | 1篇 |
儿科学 | 67篇 |
妇产科学 | 9篇 |
基础医学 | 136篇 |
口腔科学 | 23篇 |
临床医学 | 223篇 |
内科学 | 312篇 |
皮肤病学 | 35篇 |
神经病学 | 28篇 |
特种医学 | 314篇 |
外科学 | 62篇 |
综合类 | 26篇 |
预防医学 | 62篇 |
眼科学 | 6篇 |
药学 | 71篇 |
肿瘤学 | 82篇 |
出版年
2022年 | 5篇 |
2021年 | 14篇 |
2020年 | 2篇 |
2019年 | 11篇 |
2018年 | 7篇 |
2017年 | 13篇 |
2016年 | 12篇 |
2015年 | 18篇 |
2014年 | 12篇 |
2013年 | 30篇 |
2012年 | 14篇 |
2011年 | 17篇 |
2010年 | 49篇 |
2009年 | 49篇 |
2008年 | 22篇 |
2007年 | 58篇 |
2006年 | 22篇 |
2005年 | 30篇 |
2004年 | 12篇 |
2003年 | 14篇 |
2002年 | 22篇 |
2001年 | 19篇 |
2000年 | 26篇 |
1999年 | 29篇 |
1998年 | 94篇 |
1997年 | 89篇 |
1996年 | 110篇 |
1995年 | 86篇 |
1994年 | 87篇 |
1993年 | 76篇 |
1992年 | 24篇 |
1991年 | 31篇 |
1990年 | 28篇 |
1989年 | 33篇 |
1988年 | 36篇 |
1987年 | 31篇 |
1986年 | 37篇 |
1985年 | 32篇 |
1984年 | 15篇 |
1983年 | 21篇 |
1982年 | 21篇 |
1981年 | 21篇 |
1980年 | 17篇 |
1979年 | 8篇 |
1978年 | 10篇 |
1977年 | 14篇 |
1976年 | 14篇 |
1975年 | 8篇 |
1969年 | 1篇 |
1966年 | 1篇 |
排序方式: 共有1457条查询结果,搜索用时 15 毫秒
131.
Devergie A; Blaise D; Attal M; Tigaud JD; Jouet JP; Vernant JP; Bordigoni P; Ifrah N; Dauriac C; Cahn JY 《Blood》1995,85(8):2263-2268
From March 1988 to March 1991, 19 French bone marrow transplant (BMT) centers participated in a prospective randomized trial comparing two conditioning regimens for patients with chronic myeloid leukemia transplanted in first chronic phase with an HLA identical sibling donor. A total of 120 consecutive patients were randomized to receive either 120 mg/kg of cyclophosphamide followed by total body irradiation (CY-TBI; n = 55) or 16 mg/kg of busulfan followed by 120 mg/kg of CY (BU-CY; n = 65). Two different TBI regimens were used. Thirteen patients received a 10-Gy single-dose TBI (SDTBI), and 42 received a fractionated TBI (FTBI). Median time between diagnosis and BMT was 315 days. Overall 5-year actuarial survival was 62.9% (65.8% +/- 12.5% for CY-TBI and 60.6 +/- 11.7% for BU-CY; P = .5), and overall disease-free survival was 55% (51% +/- 14% for CY-TBI and 59.1% +/- 11.8% for BU-CY; P = .75). All patients conditioned with CY-TBI experienced sustained engraftment; in contrast, 4 of 65 patients conditioned with BU-CY rejected the graft (P = .18). There was no significant statistical difference between the two groups regarding transplant-related mortality (29% for CY-TBI and 38% for BU-CY; P = .44). So far, with a median follow up of 42 months, 11 patients have relapsed; 9 relapses occurred after CY-TBI, mostly after FTBI (8 of 9) and 2 after BU-CY (P = .02). The actuarial risk of relapse was 4.4% +/- 6.7% after BU-CY, 11.1% +/- 20.8% after SDTBI, and 31.3% +/- 18.1% after FTBI (P = .039). In addition, independently of the conditioning regimen, the increase of posttransplant immunosuppression in 16 patients with an anti- interleukin-2 receptor monoclonal antibody (MoAb) in addition to a short course of methotrexate and cyclosporine was shown to increase the actuarial risk of relapse (57% +/- 30% with MoAb v 9% +/- 7.3% without MoAb; P = .001). We conclude that BU is an acceptable alternative to TBI for patients with chronic myeloid leukemia in first chronic phase receiving BMT from HLA identical sibling donors. Both BU-CY and CY-TBI regimens gave similar transplant-related mortality, and the antileukemic efficiency of BU-CY regimen was either similar or even higher than that of CY-TBI. 相似文献
132.
Lauener RP; Huttner S; Buisson M; Hossle JP; Albisetti M; Seigneurin JM; Seger RA; Nadal D 《Blood》1995,86(4):1400-1407
One mechanism proposed to play a role in T-cell depletion in human immunodeficiency virus (HIV) infection is apoptosis (activation-induced cell death). We assessed whether apoptosis is related to activation of T cells in vivo and its possible triggers. DNA was extracted from peripheral blood mononuclear cells (PBMC) taken from 16 vertically HIV- infected children and 9 HIV-negative children born to HIV-positive mothers (controls) and tested by agarose gel electrophoresis for the presence of DNA fragments specific for apoptosis. Signs of apoptosis were found on in vitro culture of PBMC from 12 of 16 HIV-infected children, but not in PBMC from the nine controls. Eleven of the 12 HIV- infected children with apoptosis showed an elevated (> 15%) proportion of CD3+/HLA-DR+ cells. This was due to an increased proportion of CD8+/HLA-DR+ cells, as shown in 7 of 7 further tested patients. In none of the probands an increased (> 5%) proportion of IL-2 receptor expressing CD3+ cells was found. T cells undergoing apoptosis were preferentially of the CD8+ phenotype. Expansion of circulating CD8+/interleukin-2 receptor (IL-2R)-/HLA-DR+ T cells is known to occur during active infection with herpes viruses. To investigate the possible role of herpes viral coinfections for apoptosis in HIV infection, we focused on Epstein-Barr virus (EBV) as an example for a herpes virus usually acquired during childhood. In 10 of 12 patients with apoptosis, we found increased levels of EBV genome in PBMC and/or tissues, indicating active EBV replication. By contrast, no increased burden of EBV was found in the four HIV-infected patients without apoptosis or in the controls. Our data indicate that in children the occurrence of apoptosis in HIV infection is closely related to activation of CD8+ T cells. Furthermore, primoinfection with or reactivation of herpes viruses, such as EBV, may substantially contribute to such T-cell activation and the ensuing apoptosis. Additional studies are warranted to evaluate the contribution of herpes virus-triggered apoptosis to the T-cell loss leading to the acquired immunodeficiency syndrome. 相似文献
133.
Attal M; Blaise D; Marit G; Payen C; Michallet M; Vernant JP; Sauvage C; Troussard X; Nedellec G; Pico J 《Blood》1995,86(4):1619-1628
A prospective, randomized trial was initiated in adult acute lymphoblastic leukemia (ALL) to compare (1) disease-free survival (DFS) after allogeneic or autologous bone marrow transplantation (BMT) and (2) the relapse rate of patients treated with or without interleukin-2 (IL-2) after autologous BMT. A total of 135 previously untreated patients, aged under 55 years, received the Berlin-Frankfurt-Muster (BFM) induction regimen: 126 patients (93%), of which 120 were HLA- typed, achieved complete remission (CR). According to this genetic randomization, patients with (n = 43) or without an HLA-identical sibling (n = 77) were to receive allogeneic or autologous BMT, respectively. The 3-year post-CR probability of DFS was significantly higher in the HLA-identical sibling group than in the non-HLA-identical sibling group (68% v 26%; P < .001). Eligible patients were randomized to receive (n = 30) or not to receive (n = 30) IL-2 after autologous BMT: the 3-year post-BMT probability of continuous CR was similar in both groups (29% v 27%, respectively). We conclude that, in ALL, early allogeneic BMT after the BFM induction regimen is an effective consolidation treatment and that IL-2 does not decrease the high relapse rate observed after autologous BMT. 相似文献
134.
Graft-versus-host disease (GVHD) is currently encountered after bone marrow transplantation and transfusion. GVHD associated with transfusion (TA-GVHD) in apparently immunocompetent recipients has been recently reported with increasing frequency. A consistent finding in many of these cases is that the recipient received blood from a donor homozygous for one of the recipient's HLA haplotypes. However, the observed frequency of TA-GVHD is much lower than the estimated probability of this donor/recipient combination. The potential role of recipient immune responses in controlling TA-GVHD was investigated using an analogous murine model in which GVHD is induced by the injection of parental lymphoid cells into unirradiated F1 hybrid recipients. The effect of various immune manipulations of the recipient of GVHD induction was assessed by determining the number of donor lymphoid cells required to induce GVHD responses. Whereas depletion of recipient CD4+ cells increased the number of donor cells needed to induce GVHD, depletion of recipient CD8+ and natural killer cells resulted in fewer donor cells being needed to induce a GVHD response. These studies suggest a central role for functioning recipient CD8 and natural killer cells in the down-regulation of TA-GVHD development in recipients. 相似文献
135.
Assessment of aldehyde dehydrogenase in viable cells 总被引:3,自引:4,他引:3
Jones RJ; Barber JP; Vala MS; Collector MI; Kaufmann SH; Ludeman SM; Colvin OM; Hilton J 《Blood》1995,85(10):2742-2746
Cytosolic aldehyde dehydrogenase (ALDH), an enzyme responsible for oxidizing intracellular aldehydes, has an important role in ethanol, vitamin A, and cyclophosphamide metabolism. High expression of this enzyme in primitive stem cells from multiple tissues, including bone marrow and intestine, appears to be an important mechanism by which these cells are resistant to cyclophosphamide. However, although hematopoietic stem cells (HSC) express high levels of cytosolic ALDH, isolating viable HSC by their ALDH expression has not been possible because ALDH is an intracellular protein. We found that a fluorescent aldehyde, dansyl aminoacetaldehyde (DAAA), could be used in flow cytometry experiments to isolate viable mouse and human cells based on their ALDH content. The level of dansyl fluorescence exhibited by cells after incubation with DAAA paralleled cytosolic ALDH levels determined by Western blotting and the sensitivity of the cells to cyclophosphamide. Moreover, DAAA appeared to be a more sensitive means of assessing cytosolic ALDH levels than Western blotting. Bone marrow progenitors treated with DAAA proliferated normally. Furthermore, marrow cells expressing high levels of dansyl fluorescence after incubation with DAAA were enriched for hematopoietic progenitors. The ability to isolate viable cells that express high levels of cytosolic ALDH could be an important component of methodology for identifying and purifying HSC and for studying cyclophosphamide-resistant tumor cell populations. 相似文献
136.
Cytokine activation during attacks of the hyperimmunoglobulinemia D and periodic fever syndrome 总被引:9,自引:0,他引:9
Drenth JP; van Deuren M; van der Ven-Jongekrijg J; Schalkwijk CG; van der Meer JW 《Blood》1995,85(12):3586-3593
The hyperimmunoglobulinemia D and periodic fever (hyper-IgD) syndrome is typified by recurrent febrile attacks with abdominal distress, joint involvement (arthralgias/arthritis), headache, skin lesions, and an elevated serum IgD level (> 100 U/mL). This familial disorder has been diagnosed in 59 patients, mainly from Europe. The pathogenesis of this febrile disorder is unknown, but attacks are joined by an acute-phase response. Because this response is considered to be mediated by cytokines, we measured the acute-phase proteins C-reactive protein (CRP) and soluble type-II phospholipase A2 (PLA2) together with circulating concentrations and ex vivo production of the proinflammatory cytokines interleukin-1 alpha (IL-1 alpha), IL-1 beta, IL-6, and tumor necrosis factor alpha (TNF alpha) and the inhibitory compounds IL-1 receptor antagonist (IL-1ra), IL-10, and the soluble TNF receptors p55 (sTNFr p55) and p75 (sTNFr p75) in 22 patients with the hyper-IgD syndrome during attacks and remission. Serum CRP and PLA2 concentrations were elevated during attacks (mean, 213 mg/L and 1,452 ng/mL, respectively) and decreased between attacks. Plasma concentrations of IL-1 alpha, IL-1 beta, or IL-10 were not increased during attacks. TNF alpha concentrations were slightly, but significantly, higher with attacks (104 v 117 pg/mL). Circulating IL-6 values increased with attacks (19.7 v 147.9 pg/mL) and correlated with CRP and PLA2 values during the febrile attacks. The values of the antiinflammatory compounds IL-1ra, sTNFr p55, and sTNFr p75 were significantly higher with attacks than between attacks, and there was a significant positive correlation between each. The ex-vivo production of TNF alpha, IL-1 beta, and IL-1ra was significantly higher with attacks, suggesting that the monocytes/macrophages were already primed in vivo to produce increased amounts of these cytokines. These findings point to an activation of the cytokine network, and this suggests that these inflammatory mediators may contribute to the symptoms of the hyper-IgD syndrome. 相似文献
137.
HLA-DRB1*04 subtypes are associated with increased inflammatory activity in early rheumatoid arthritis 总被引:1,自引:2,他引:1
Seidl C; Koch U; Buhleier T; Frank R; Moller B; Markert E; Koller-Wagner G; Seifried E; Kaltwasser JP 《Rheumatology (Oxford, England)》1997,36(9):941-944
The sequence polymorphism of HLA-DRB1 molecules in 84 rheumatoid arthritis
(RA) patients with early RA has been analysed to evaluate whether
particular HLA-DR alleles influence disease progression in the early stage
of the disease. Clinical data were analysed by grouping the patients
according to disease-associated haplotype combinations
(DRB1*04,04/DRB1*04,01/DRB1*04,X/DRB1*01,X) in comparison to patients who
did not carry these haplotypes (DRB1*X,X). Our results indicate that
patients with early RA who are homozygous for DRB1*04 exhibit an elevated
inflammatory activity and an increase of joint affections. In addition, the
amino acid polymorphism (QR/KRAA) at position 70-74 seems to affect the
production of rheumatoid factors. These results support the role of
HLA-DRB1 alleles in the pathogenesis of RA and indicate that patients with
particular HLA-DRB1*04 haplotype combinations may require intensified
therapeutic interventions in the early stage of the disease to prevent
disease progression.
相似文献
138.
139.
Foreyt JP Poston WSC 《中国组织工程研究与临床康复》2001,5(13):24-26
2型糖尿病(2-DM)与肥胖、肾病、微血管病和动脉粥样硬化有关。因为该病的并发症及慢性化,所以通过改变生活方式而降低饮食、起居方面的危险因素,对2-DM患者长期健康是极为重要的。患者要学会、低脂的饮食习惯和正规的运动模式。本文要介绍针对肥胖的糖尿病患者生活方式的改良。还将讨论一些关于改变生活方式和提高长期随访率的困难。最后,我们要介绍2-DM高危人群,在美国的墨西哥人是怎样实施这些方案的。 相似文献
140.
Effects of interleukin-11 on the proliferation and cell cycle status of myeloid leukemic cells 总被引:1,自引:0,他引:1
Interleukin-11 (IL-11) is a pleiotropic cytokine with effects on many different targets. Within the hematopoietic system, the effects of IL- 11 are largely manifest only through combination with other cytokines, including IL-3 and Steel factor (SF). In the present study, we addressed the question of IL-11 responsiveness within the different types of human leukemic cells, as well as the mechanism of action of IL- 11 at the cellular level. Analysis of a panel of samples from different patients with acute myeloblastic leukemia (AML) and myeloid leukemic cell lines indicated that IL-11 alone was ineffective in supporting myeloid leukemic cell growth but frequently enhanced growth supported by IL-3, granulocyte-macrophage colony-stimulating factor (GM-CSF), or SF. In contrast, three acute pre-B lymphocytic leukemia (pre-B-ALL) and two acute T lymphocytic leukemia (T-ALL) lines failed to respond to IL- 11 alone or when combined with other cytokines. The growth enhancement of IL-11 among the AML patient samples was dose dependent and remarkably constant with half-efficient concentrations in the range of 0.3 to 0.4 ng/mL. The thymidine suicide studies with the patient samples revealed that 40% to 50% of the blast cells were in S-phase when exposed for 16 hours to IL-3 and this level was increased to 70% to 90% in response to either IL-11 or IL-6. Our data suggest that the latter two interleukins act synergistically with the direct mitogenic factor, IL-3, in triggering AML blast-cell proliferation. Detailed analysis with several patient samples further revealed that SF and IL- 11 both enhance IL-3-supported clonogenic growth of AML blasts and the combination of all three growth factors yields optimal growth. In contrast, IL-6 does not further enhance the effect of IL-11. These results indicate that SF and IL-11 enhance IL-3-dependent clonogenic growth through two distinct pathways, whereas IL-6 and IL-11 may trigger the same pathway. 相似文献